PT3186257T - Novo derivado de oxima de cromona e a sua utilização como modulador alostérico de receptores metabotrópicos de glutmato - Google Patents

Novo derivado de oxima de cromona e a sua utilização como modulador alostérico de receptores metabotrópicos de glutmato

Info

Publication number
PT3186257T
PT3186257T PT15770814T PT15770814T PT3186257T PT 3186257 T PT3186257 T PT 3186257T PT 15770814 T PT15770814 T PT 15770814T PT 15770814 T PT15770814 T PT 15770814T PT 3186257 T PT3186257 T PT 3186257T
Authority
PT
Portugal
Prior art keywords
metabotropic glutamate
glutamate receptors
allosteric modulator
oxime derivative
novel chromone
Prior art date
Application number
PT15770814T
Other languages
English (en)
Portuguese (pt)
Inventor
Pomel Vincent
Charvin Delphine
Manteau Baptiste
Conquet François
Original Assignee
Prexton Therapeutics Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prexton Therapeutics Sa filed Critical Prexton Therapeutics Sa
Publication of PT3186257T publication Critical patent/PT3186257T/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Nutrition Science (AREA)
  • Addiction (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Physiology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PT15770814T 2014-08-27 2015-08-27 Novo derivado de oxima de cromona e a sua utilização como modulador alostérico de receptores metabotrópicos de glutmato PT3186257T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP14182468 2014-08-27

Publications (1)

Publication Number Publication Date
PT3186257T true PT3186257T (pt) 2019-03-27

Family

ID=51421865

Family Applications (1)

Application Number Title Priority Date Filing Date
PT15770814T PT3186257T (pt) 2014-08-27 2015-08-27 Novo derivado de oxima de cromona e a sua utilização como modulador alostérico de receptores metabotrópicos de glutmato

Country Status (26)

Country Link
US (3) US10017521B2 (cg-RX-API-DMAC7.html)
EP (3) EP3186257B1 (cg-RX-API-DMAC7.html)
JP (1) JP6430015B2 (cg-RX-API-DMAC7.html)
KR (1) KR101870589B1 (cg-RX-API-DMAC7.html)
CN (2) CN110343118A (cg-RX-API-DMAC7.html)
AU (1) AU2015308438B2 (cg-RX-API-DMAC7.html)
CA (1) CA2956191C (cg-RX-API-DMAC7.html)
CY (1) CY1121352T1 (cg-RX-API-DMAC7.html)
DK (1) DK3186257T3 (cg-RX-API-DMAC7.html)
ES (1) ES2714073T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20190343T1 (cg-RX-API-DMAC7.html)
HU (1) HUE041941T2 (cg-RX-API-DMAC7.html)
IL (1) IL250287B (cg-RX-API-DMAC7.html)
LT (1) LT3186257T (cg-RX-API-DMAC7.html)
MA (3) MA52702A (cg-RX-API-DMAC7.html)
ME (1) ME03339B (cg-RX-API-DMAC7.html)
MX (1) MX369643B (cg-RX-API-DMAC7.html)
NZ (1) NZ728853A (cg-RX-API-DMAC7.html)
PL (1) PL3186257T3 (cg-RX-API-DMAC7.html)
PT (1) PT3186257T (cg-RX-API-DMAC7.html)
RS (1) RS58592B1 (cg-RX-API-DMAC7.html)
RU (1) RU2672569C2 (cg-RX-API-DMAC7.html)
SI (1) SI3186257T1 (cg-RX-API-DMAC7.html)
SM (1) SMT201900152T1 (cg-RX-API-DMAC7.html)
TR (1) TR201903332T4 (cg-RX-API-DMAC7.html)
WO (1) WO2016030444A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3186257B1 (en) 2014-08-27 2019-02-06 Prexton Therapeutics SA Novel chromone oxime derivative and its use as allosteric modulator of metabotropic glutamate receptors
RS59651B1 (sr) 2015-08-27 2020-01-31 Prexton Therapeutics Sa Derivat hromonoksima koji prodire u mozak u svrhu terapije diskinezije uzrokovane levodopom
MX2021000841A (es) 2018-07-26 2021-03-26 Domain Therapeutics Derivados de quinazolinona sustituidos y su uso como moduladores alostericos positivos de mglur4.

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4065467A (en) 1973-12-27 1977-12-27 Carlo Erba, S. P. A. 5:6-Benzo δ-pyrone derivatives and process for their preparation
US4777252A (en) 1987-08-13 1988-10-11 E. R. Squibb & Sons, Inc. 2-oxo-1-[[(substituted sulfonyl)amino]-carbonyl]azetidines
JP3993651B2 (ja) 1994-10-21 2007-10-17 アスビオファーマ株式会社 シクロプロパクロメンカルボン酸誘導体
EP1298129A3 (en) 2001-09-28 2003-06-04 Central Glass Company, Limited Process for producing 4-sustituted benzopyran derivatives
MY141521A (en) 2002-12-12 2010-05-14 Hoffmann La Roche 5-substituted-six-membered heteroaromatic glucokinase activators
JP2006522124A (ja) 2003-04-03 2006-09-28 バーテックス　ファーマシューティカルズ　インコーポレイテッド プロテインキナーゼのインヒビターとして有用な組成物
WO2007011701A1 (en) 2005-07-15 2007-01-25 Transform Pharmaceuticals, Inc. Novel hydrochloride salts of levodopa
EA201070143A1 (ru) 2007-07-13 2010-08-30 Аддекс Фарма С.А. Новые гетероароматические производные и их использование в качестве положительных аллостерических модуляторов метаботропных глутаматных рецепторов
GB0713686D0 (en) 2007-07-13 2007-08-22 Addex Pharmaceuticals Sa New compounds 2
AU2010311321B2 (en) * 2009-10-30 2014-11-27 Prexton Therapeutics S.A. Novel oxime derivatives and their use as allosteric modulators of metabotropic glutamate receptors
SG181498A1 (en) * 2009-12-04 2012-07-30 Sunovion Pharmaceuticals Inc Multicyclic compounds and methods of use thereof
WO2013107862A1 (en) * 2012-01-18 2013-07-25 Addex Pharma S.A. NOVEL 2-AMINO-4,5,6,8-TETRAHYDROPYRAZOLO[3,4-b]THIAZOLO [4,5-d]AZEPINE DERIVATIVES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS
EP3186257B1 (en) * 2014-08-27 2019-02-06 Prexton Therapeutics SA Novel chromone oxime derivative and its use as allosteric modulator of metabotropic glutamate receptors
RS59651B1 (sr) 2015-08-27 2020-01-31 Prexton Therapeutics Sa Derivat hromonoksima koji prodire u mozak u svrhu terapije diskinezije uzrokovane levodopom

Also Published As

Publication number Publication date
KR20170042624A (ko) 2017-04-19
MA48048A (fr) 2020-02-12
TR201903332T4 (tr) 2019-03-21
LT3186257T (lt) 2019-04-25
AU2015308438B2 (en) 2018-12-13
MX369643B (es) 2019-11-15
EP3502115A1 (en) 2019-06-26
HRP20190343T1 (hr) 2019-05-31
MA52702A (fr) 2021-03-31
EP3186257B1 (en) 2019-02-06
ME03339B (me) 2019-10-20
US10442818B2 (en) 2019-10-15
CA2956191C (en) 2020-01-28
EP3186257A1 (en) 2017-07-05
US20180291034A1 (en) 2018-10-11
HUE041941T2 (hu) 2019-06-28
PL3186257T3 (pl) 2019-07-31
IL250287A0 (en) 2017-03-30
CY1121352T1 (el) 2020-05-29
AU2015308438A1 (en) 2017-03-02
RS58592B1 (sr) 2019-05-31
CN106715444A (zh) 2017-05-24
CN110343118A (zh) 2019-10-18
EP3696183A1 (en) 2020-08-19
US20170253613A1 (en) 2017-09-07
JP6430015B2 (ja) 2018-11-28
MA40530A (fr) 2017-07-05
DK3186257T3 (en) 2019-04-01
RU2672569C2 (ru) 2018-11-16
US10017521B2 (en) 2018-07-10
CN106715444B (zh) 2019-07-12
JP2017525776A (ja) 2017-09-07
WO2016030444A1 (en) 2016-03-03
MX2017002429A (es) 2017-08-02
RU2017109818A (ru) 2018-10-01
NZ728853A (en) 2018-04-27
IL250287B (en) 2020-02-27
CA2956191A1 (en) 2016-03-03
US20200024285A1 (en) 2020-01-23
RU2017109818A3 (cg-RX-API-DMAC7.html) 2018-10-01
KR101870589B1 (ko) 2018-06-25
SMT201900152T1 (it) 2019-05-10
SI3186257T1 (sl) 2019-07-31
ES2714073T3 (es) 2019-05-27

Similar Documents

Publication Publication Date Title
IL272888B1 (en) Uses of piperidinyl-indole derivatives
LT3322701T (lt) Etinilo dariniai kaip metabotropinių glutamato receptorių moduliatoriai
ZA201700304B (en) Spirocycloheptanes as inhibitors of rock
IL250511A0 (en) Crystalline forms of ibrutinib
EP3125884A4 (en) Small molecule inhibitors of mcl-1 and uses thereof
HUE057895T2 (hu) Lizinspecifikus demetiláz-1 inhibitorai
HUE062558T2 (hu) Lizinspecifikus demetiláz-1 inhibitorok
EP3160970A4 (en) Synthesis of halichondrin analogs and uses thereof
SMT201900706T1 (it) Tiazoli sostituiti con ammide come modulatori di rorgammat
IL249348A0 (en) A new preparation and method for synthesis
IL250287A0 (en) A new derivative of chromone oxime and its use as an allosteric modulator of metabotropic glutamate receptors
IL251230A0 (en) Converted pyrazoloquinazolinones and pyrroloquinazolinones as allosteric modulators of group ii metabotropic glutamate receptors
ZA201701976B (en) Synthesis of ent-progesterone and intermediates thereof
EP3216799A4 (en) New type of cytidine derivative dimer and application thereof
IL250846A0 (en) Synthesis of cyclocreatin and its analogs
IL252947A0 (en) Total synthesis of trioxacarcin dc-45-a2 and preparation of trioxacarcin analogs
ZA201704416B (en) Heterocyclylalkyne derivatives and their use as modulators of mglur5 receptors
AU2015905333A0 (en) Modulators of Endosomal G Protein-Coupled Receptors
SG11201605485QA (en) Synthesis method of 9-allylcamptothecin derivatives
HK1236098A1 (en) Modulators of androgen synthesis